eprintid: 10113058
rev_number: 62
eprint_status: archive
userid: 608
dir: disk0/10/11/30/58
datestamp: 2020-10-26 17:30:32
lastmod: 2021-12-05 00:21:10
status_changed: 2020-10-26 17:30:32
type: article
metadata_visibility: show
creators_name: Ray, S
creators_name: Jones, R
creators_name: Pritchard-Jones, K
creators_name: Dzhuma, K
creators_name: van den Heuvel-Eibrink, M
creators_name: Tytgat, G
creators_name: van der Beek, J
creators_name: Oades, G
creators_name: Murphy, D
title: Pediatric and young adult renal cell carcinoma
ispublished: pub
divisions: UCL
divisions: B02
divisions: D13
divisions: G22
keywords: Science & Technology, Life Sciences & Biomedicine, Oncology, Hematology, Pediatrics, pediatrics, renal cell carcinoma, targeted therapy, treatment, NEPHRON-SPARING SURGERY, LYMPH-NODE INVOLVEMENT, OPEN-LABEL, RECOMBINANT INTERLEUKIN-2, RANDOMIZED PHASE-3, COMPLETE RESPONSE, CHILDREN, THERAPY, TUMORS, EVEROLIMUS
note: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
abstract: Renal cell carcinoma (RCC) is rare in children but is the most common renal tumor in adults. Pediatric RCC has different clinical characteristics, histopathology, and treatment compared with adult disease. Databases were reviewed from inception to February 2020, identifying 32 publications pertaining to 350 patients under 27 years. Surgery is the cornerstone for cure in localized RCC. Lymph node dissection remains controversial. Conventional radiotherapy has no curative role in RCC; similarly, conventional chemotherapy has not proven to be effective in large cohorts. Pediatric metastatic RCC has a poor outlook. There are no published prospective studies demonstrating which adjuvant therapy could improve outcome. Sunitinib, a tyrosine kinase inhibitor, is recommended in this group despite limited evidence. This review provides an overview for pediatric RCC, including the evolving role of precision medicine.
date: 2020-09-01
date_type: published
publisher: WILEY
official_url: https://doi.org/10.1002/pbc.28675
oa_status: green
full_text_type: other
language: eng
primo: open
primo_central: open_green
verified: verified_manual
elements_id: 1812787
doi: 10.1002/pbc.28675
lyricists_name: Dzhuma, Kristina
lyricists_name: Pritchard-Jones, Kathryn
lyricists_id: KDZHU50
lyricists_id: KPPRI20
actors_name: Stacey, Thomas
actors_id: TSSTA20
actors_role: owner
full_text_status: public
publication: Pediatric Blood & Cancer
volume: 67
number: 11
article_number: e28675
pages: 13
citation:        Ray, S;    Jones, R;    Pritchard-Jones, K;    Dzhuma, K;    van den Heuvel-Eibrink, M;    Tytgat, G;    van der Beek, J;         ... Murphy, D; + view all <#>        Ray, S;  Jones, R;  Pritchard-Jones, K;  Dzhuma, K;  van den Heuvel-Eibrink, M;  Tytgat, G;  van der Beek, J;  Oades, G;  Murphy, D;   - view fewer <#>    (2020)    Pediatric and young adult renal cell carcinoma.                   Pediatric Blood & Cancer , 67  (11)    , Article e28675.  10.1002/pbc.28675 <https://doi.org/10.1002/pbc.28675>.       Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10113058/4/Figure%201%20flow%20chart.pdf
document_url: https://discovery.ucl.ac.uk/id/eprint/10113058/12/Supporting%20Info%20Figure%20S1.pdf
document_url: https://discovery.ucl.ac.uk/id/eprint/10113058/19/Pritchard-Jones_PBC%20Final%20Submission%2011th%20August.pdf
document_url: https://discovery.ucl.ac.uk/id/eprint/10113058/25/Pritchard-Jones_Table%201%20pt%20characteristicsDOCX.pdf
document_url: https://discovery.ucl.ac.uk/id/eprint/10113058/33/Pritchard-Jones_Supporting%20Info%20Table%20S1.pdf
document_url: https://discovery.ucl.ac.uk/id/eprint/10113058/40/Pritchard-Jones_Supporting%20Figure%20S2%20DOCX.pdf